An Observational Study of Dutasteride and Alpha-blocker Combination Therapy in Men With Symptomatic Benign Prostatic Hyperplasia and PSA Level Over 4 ng/mL

Inclusion Criteria: * Males, age ≧ 50 years * Clinical diagnosis of BPH by medical history and physical examination, including a digital rectal examination (DRE) * IPSS score ≧ 8 points and prostate volume ≧ 30 mL * Total serum PSA ≧ 4.0 ng/mL and ≦ 20 ng/mL at screening * Previous TRUS-guided biopsy have been done with benign findings and with prostate cancer (CaP) not detected within the past 6 months. * Dutasteride combination therapy will be allowed by investigator's prescription * Ability to understand and willingly provide written informed consent Exclusion Criteria: * History or evidence of prostate cancer and high grade prostatic intraepithelial neoplasia (HGPIN) * With symptomatic urinary tract or prostate infection or urinary retention within 3 months prior to entry of study * Use of finasteride within 6 months of screening visit * Use of dutasteride within 12 months of screening visit